Die nächste Microsoft im Bereich der Stammzellen?

#62">

Fourth Quarter 2017 Financial Highlights
Total net revenues increased 41% to $23.4 million compared to $16.5 million in the fourth quarter of 2016; excluding license revenue, net revenue increased 34% to $22.2 million;
Gross margins of 64% compared to gross margins of 54% in the fourth quarter of 2016;
Operating income of $1.2 million, compared to operating loss of $5.9 million in the fourth quarter of 2016;
Net income of $0.3 million, or $0.01 per share, compared to net loss of $6.2 million, or $0.34 per share, in the fourth quarter of 2016; and
As of December 31, 2017, the company had $26.9 million in cash compared to $23.0 million in cash at December 31, 2016.
Full Year 2017 Financial Highlights
Total net revenue increased 18% to $63.9 million compared to $54.4 million in 2016; excluding license revenue, net revenue increased 15% to $62.8 million;
Gross margins of 53% compared to gross margins of 48% in 2016;
Operating loss of $15.0 million, compared to operating loss of $19.2 million in 2016; and
Net loss of $17.3 million, or $0.52 per share, compared to net loss of $19.6 million, or $1.18 per share, in 2016.
Recent Business Highlights
During and since the fourth quarter of 2017, the company:
Achieved record fourth quarter revenues and the third straight quarter of 30% or greater revenue growth versus the same quarter of the prior year;
Trained approximately 600 surgeons on the MACI® (autologous cultured chondrocytes on porcine collage membrane) surgical procedure to date;
Increased MACI biopsies 48% in the fourth quarter of 2017 compared to the same period in 2016, the second consecutive quarter with over 40% growth versus the same quarter of the prior year;